28 May 2026, 7:16 pmCorp. Action
Corporate Action-Board approves Dividend
Dividend PDF
Loading page…
NG Industries Ltd operates in Healthcare Service Provider within the Healthcare sector.
Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
Standalone figures
| Ratio | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross margin % | — | — | 73% | 64.3% | 63.4% | 74.2% | 74.1% | 73.9% |
| EBITDA margin % | 15.5% | 14.7% | 10.1% | 12.4% | 9.6% | 11.7% | 10.8% | 10.8% |
| EBIT margin % | 12.2% | 11.6% | 6% | 9.3% | 6.8% | 8.1% | 7.1% | 7.2% |
| PAT margin % | 6.4% | 8% | 5.1% | 14.2% | 44.5% | 29.8% | 46.8% | 10.6% |
| Working capital | ||||||||
| Receivable days | — | — | 10 | 15 | 1 | 3 | 9 | 11 |
| Inventory days | — | — | 65 | 156 | 35 | 53 | 64 | 70 |
| Payable days | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| NWC days | — | — | 75 | 171 | 36 | 56 | 73 | 81 |
| Leverage | ||||||||
| Current ratio | — | — | 1.29 | 3.1 | 1.6 | 2.87 | 1.66 | 9.8 |
| Debt to EBITDA | — | — | 0.23 | 0.22 | 0.33 | 0.6 | 0.99 | 0.91 |
| Debt to equity | — | — | 0.02 | 0.02 | 0.02 | 0.03 | 0.05 | 0.05 |
| Interest coverage | 18.2 | 23.4 | 43 | 167 | 966 | 294 | 229.5 | 31.6 |
| Asset turnover | — | — | 0.7 | 0.68 | 0.61 | 0.42 | 0.4 | 0.46 |
| Return ratios | ||||||||
| Return on assets % | — | — | 3.6% | 9.6% | 27.1% | 12.6% | 18.6% | 4.9% |
| Return on capital employed % | — | — | 5.7% | 16.5% | 35.6% | 17.5% | 23.7% | 5.9% |
| Return on equity % | — | — | 4.1% | 10.9% | 29.5% | 13.9% | 20.1% | 5.2% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
No scheme among the 32 fund houses on record reported a position in NG Industries Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd.LALPATHLABLALPATHLAB | ₹33,605 Cr | ₹33,605 Cr | ₹2,891 Cr | ₹838 Cr | 28.3% | ₹542 Cr | 18.5% | 28.8% | 21.6% | -79 |
| Vijaya Diagnostic Centre LimitedVIJAYAVIJAYA | ₹14,694 Cr | ₹14,694 Cr | ₹857 Cr | ₹362 Cr | 41.4% | ₹187 Cr | 21.3% | 21.3% | 19.7% | -117 |
| Metropolis Healthcare LimitedMETROPOLISMETROPOLIS | ₹11,151 Cr | ₹11,169 Cr | ₹1,710 Cr | ₹422 Cr | 24.4% | ₹202 Cr | 11.6% | 17.3% | 13.4% | -57 |
| Thyrocare Technologies LimitedTHYROCARETHYROCARE | ₹8,495 Cr | ₹8,495 Cr | ₹876 Cr | ₹282 Cr | 31.6% | ₹176 Cr | 19.6% | 36.5% | 28.8% | 4 |
| Nephrocare Health Services LimitedNEPHROPLUSNEPHROPLUS | ₹6,509 Cr | ₹6,589 Cr | ₹999 Cr | ₹227 Cr | 22.7% | ₹77 Cr | 7.7% | 17.1% | 9.1% | -61 |
| Suraksha Diagnostic LimitedSURAKSHASURAKSHA | ₹1,824 Cr | ₹1,826 Cr | ₹325 Cr | ₹102 Cr | 30.7% | ₹36 Cr | 10.1% | 16.8% | 14.1% | -101 |
| Krsnaa Diagnostics LimitedKRSNAAKRSNAA | ₹1,798 Cr | ₹2,332 Cr | ₹815 Cr | ₹218 Cr | 27.4% | ₹97 Cr | 13.1% | 13.1% | 10.9% | 65 |
| 3b Blackbio Dx Limited3BBLACKBIO3BBLACKBIO | ₹1,416 Cr | ₹1,417 Cr | ₹96 Cr | ₹50 Cr | 52% | ₹163 Cr | 49.4% | 25.3% | 19.4% | 235 |
| One Global Service Provider LtdONEGLOBALONEGLOBAL | ₹1,025 Cr | ₹1,025 Cr | ₹6 Cr | ₹1 Cr | 22.2% | ₹1 Cr | 17.3% | 17.6% | 19.5% | — |
| Health X Platform LimitedHEALTHXHEALTHX | ₹868 Cr | ₹890 Cr | ₹1,468 Cr | ₹-67 Cr | -4% | ₹-20 Cr | -0.1% | — | 0.2% | — |
| Gaudium Ivf And Women Health LimitedGAUDIUMIVFGAUDIUMIVF | ₹797 Cr | ₹820 Cr | ₹104 Cr | ₹38 Cr | 36.1% | ₹24 Cr | 23.4% | 23.1% | 16.1% | 92 |
| Aspira Pathlab & Diagnostics LtdASPIRAASPIRA | ₹135 Cr | ₹136 Cr | ₹22 Cr | ₹4 Cr | 16% | ₹2 Cr | 9.2% | 17.5% | 18.1% | 16 |
| Holder (%) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74.5% | 74.5% | 74.5% | 74.5% | 74.5% | 74.5% | 74.5% | 74.5% | 74.5% | 74.5% | 74.5% | 74.5% | |
| FII | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DII | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 25.5% | 25.5% | 25.5% | 25.5% | 25.5% | 25.5% | 25.5% | 25.5% | 25.5% | 25.5% | 25.5% | 25.5% | |
| No. of shareholders | — | — | — | — | — | — | — | — | 2,250 | 2,220 | 2,166 | 2,161 |
Promoter holding up 0 percentage points since Sep 2023.
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 15 Nov 2023 | ASCENT FINSERV | Bulk | BSE | Buy | 17,763 | ₹154.85 | ₹0.28 Cr |
| 15 Nov 2023 | ASCENT FINSERV | Bulk | BSE | Sell | 9,263 | ₹168.00 | ₹0.16 Cr |
| 5 Jul 2023 | YASHIKA NAYAN DOSHI | Bulk | BSE | Buy | 20,271 | ₹135.85 | ₹0.28 Cr |
| 5 Jul 2023 | YASHIKA NAYAN DOSHI | Bulk | BSE | Sell | 14,771 | ₹137.37 | ₹0.20 Cr |
| 30 Jun 2023 | KARANKUMAR KANUJI THAKOR | Bulk | BSE | Sell | 28,321 | ₹106.50 | ₹0.30 Cr |
| 30 Jun 2023 | KARANKUMAR KANUJI THAKOR | Bulk | BSE | Buy | 28,321 | ₹101.42 | ₹0.29 Cr |
| 30 Jun 2023 | SINGHI DINESH KUMAR (HUF) | Bulk | BSE | Sell | 18,000 | ₹100.00 | ₹0.18 Cr |
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Documents link to external sources (exchange filings, company investor pages).
Corporate Action-Board approves Dividend
Board Meeting Outcome for Financial Results For Quarter And Year Ended 31St March 2026
Financial Results For Quarter And Year Ended 31St March, 2026
Board Meeting Intimation for Consideration And Approval Of 1. Audited Financial Results Of The Company For The Quarter And Year Ended 31St March, 2026 And 2. Dividend For The Financial Year Ended 31St March, 2026 Subject To Approval Of The Shareholders At The Ensuing AGM.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Announcement under Regulation 30 (LODR)-Newspaper Publication
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
| Date | Category | Subject | Filing |
|---|---|---|---|
| 28 May 2026, 7:16 pm | Corp. Action Dividend | Corporate Action-Board approves Dividend | |
| 28 May 2026, 7:00 pm | Board Meeting Outcome of Board Meeting | Board Meeting Outcome for Financial Results For Quarter And Year Ended 31St March 2026 |
| 28 May 2026, 6:57 pm | Result Financial Results | Financial Results For Quarter And Year Ended 31St March, 2026 |
| 18 May 2026, 5:37 pm | Board Meeting | Board Meeting Intimation for Consideration And Approval Of 1. Audited Financial Results Of The Company For The Quarter And Year Ended 31St March, 2026 And 2. Dividend For The Financial Year Ended 31St March, 2026 Subject To Approval Of The Shareholders At The Ensuing AGM. |
| 8 May 2026, 5:48 pm | Company Update Newspaper Publication | Announcement under Regulation 30 (LODR)-Newspaper Publication |
| 18 Apr 2026, 6:24 pm | Others Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A |
| 11 Apr 2026, 1:31 pm | Company Update Newspaper Publication | Announcement under Regulation 30 (LODR)-Newspaper Publication |
| 8 Apr 2026, 8:04 pm | Company Update Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 |
| ₹ Cr | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 | 17 | 17 | 18 | 19 | 12 | 18 | 19 | 17 | 17 | 16 | |
| COGS | — | — | — | -5 | -5 | 3 | 7 | 7 | 4 | 4 | 4 |
| Gross profit | — | — | — | — | — | 9 | 12 | 12 | 13 | 12 | 12 |
| 14 | 15 | 15 | 20 | 21 | 7 | 10 | 10 | 11 | 10 | 10 | |
| 3 | 3 | 3 | 3 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | |
| OPM % | 14.8% | 14.6% | 15.6% | 15.5% | 14.7% | 10.1% | 12.4% | 9.6% | 11.7% | 10.8% | 10.8% |
| Depreciation | — | — | — | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| -0 | -0 | -0 | -0 | -0 | 0 | 2 | 8 | 5 | 8 | 1 | |
| Profit before tax | 2 | 2 | 2 | 2 | 2 | 1 | 3 | 10 | 6 | 9 | 2 |
| Tax | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 |
| Tax % | 36.4% | 36% | 34.1% | 34.7% | 27.6% | 26.5% | 21.4% | 13.8% | 14% | 15.3% | 19.1% |
| 2 | 1 | 1 | 1 | 1 | 1 | 3 | 8 | 5 | 8 | 2 | |
| PAT margin % | 9% | 8.2% | 8.1% | 6.4% | 8% | 5.1% | 14.2% | 44.5% | 29.8% | 46.8% | 10.6% |
| EPS (₹) | 4.6 | — | 4.2 | — | 4.4 | 1.8 | — | 24.8 | 15 | 23.1 | 5.2 |
| EPS adjusted (₹) | — | — | — | — | 4.4 | 1.8 | 7.8 | 24.8 | 15 | 23.1 | 5.2 |
| 76.6% | — | 83.3% | — | 0% | 0% | — | 14.1% | 23.3% | 15.2% | 67.7% | |
| Annual report | Annual report for Mar 2016 | Annual report for Mar 2017 | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | — | 12 | 21 | 25 | 33 | 35 | 30 |
| — | 0 | 1 | 1 | 1 | 2 | 2 | |
| — | 2 | 3 | 2 | 3 | 1 | 0 | |
| Total equity & liabilities | — | 17 | 27 | 31 | 40 | 42 | 35 |
| 5 | 5 | 6 | 5 | 6 | 6 | 5 | |
| CWIP | — | — | — | — | — | 0 | — |
| Investments | — | 8 | 16 | 22 | 29 | 32 | 26 |
| — | 4 | 5 | 3 | 5 | 4 | 4 | |
| Total assets | — | 17 | 27 | 31 | 40 | 42 | 35 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 1 | -2 | 3 | -1 | 2 | 1 | |
| 2 | 1 | -2 | 2 | -1 | -0 | |
| -3 | 0 | -1 | -1 | -1 | -1 | |
| Net cash flow | 1 | -0 | 0 | 1 | -0 | -1 |
| Free cash flow | 1 | -3 | 3 | -2 | 1 | 1 |
| CFO / Operating profit % | 112.5% | -75.6% | 175.6% | -51.8% | 101.1% | 54.2% |